Finasteride

ELEVIDYS (delandistrogene moxeparvovec-rokl) Hepatotoxicity-associated fatalities in non-ambulatory patients with Duchenne muscular dystrophy FDA is evaluating the need for regulatory action. FDA Safety Communication was issued on June 24, 2025: FDA Investigating Deaths Due to Acute Liver Failure in Non-ambulatory Duchenne Muscular Dystrophy Patients Following ELEVIDYS Finasteride (compounded product) topical Adverse event FDA alerts health care providers, compounders and consumers of potential risks associated with compounded topical finasteride products Janus kinase (JAK) inhibitors Cerebral venous sinus thrombosis FDA is evaluating the need for regulatory action. Leqembi (lecanemab-irmb) injection Amyloid related imaging abnormality-edema/effusion FDA is evaluating the need for regulatory action. Ocaliva (obeticholic acid) tablets Liver disorder FDA is evaluating the need for regulatory action. Olanzapine-containing products Lybalvi (olanzapine and samidorphan) tablets Symbyax (olanzapine and fluoxetine) capsules Zyprexa (olanzapine) tablets Zyprexa Intramuscular (olanzapine) injection Zyprexa Relprevv (olanzapine) injectable suspension Zyprexa Zydis (olanzapine) tablets Inappropriate antidiuretic hormone secretion FDA is evaluating the need for regulatory action. Poly (ADP-ribose) polymerase (PARP) inhibitors Akeega (niraparib and abiraterone acetate) tablets Lynparza (olaparib) tablets Rubraca (rucaparib) tablets Talzenna (talazoparib) capsules Zejula (niraparib) tablets Vasculitis FDA is evaluating the need for regulatory action. Rilutek (riluzole) tablets Tiglutik (riluzole) oral suspension Pancreatitis acute FDA is evaluating the need for regulatory action. Suprep Bowel Pre Kit (sodium sulfate, potassium sulfate, and magnesium sulfate) oral solution Hypersensitivity FDA is evaluating the need for regulatory action. Vyvgart Hytrulo (efgartigimod alfa and hyaluronidase-qvfc) injection Severe worsening of chronic inflammatory demyelinating polyradiculoneuropathy FDA is evaluating the need for regulatory action. Xcopri (cenobamate tablets) Drug-induced liver injury FDA is evaluating the need for regulatory action. Legal Disclaimer: EIN Presswire provides this news content "as is" without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the author above.

New Research Highlights DHT’s Role in Prostate Health and Emerging Therapies to Manage Hormone Imbalance Understanding the role of dihydrotestosterone (DHT) is essential for those undergoing testosterone replacement therapy.” — Chris Rue, FNP-C NEW ORLEANS, LA, UNITED STATES, June 6, 2025 / EINPresswire.com / -- Dihydrotestosterone (DHT), a potent androgen derived from testosterone, plays a critical role in the development and maintenance of male characteristics. However, medical experts and researchers are sounding the alarm about its potential impact on prostate health, especially when levels become elevated. DHT is primarily synthesized in the prostate, liver, skin, and hair follicles through the enzymatic conversion of testosterone by 5-alpha reductase. While essential for male development, excessive DHT levels have been strongly linked to benign prostatic hyperplasia (BPH) and an increased risk of prostate enlargement, which can lead to urinary problems and decreased quality of life in aging men. Effects of Elevated DHT on the Prostate: • Prostate Enlargement: Elevated DHT stimulates excessive growth of prostate tissue, contributing to BPH. • Urinary Symptoms: Increased prostate volume can compress the urethra, causing frequent urination, difficulty starting urination, and weak urinary flow. • Potential Cancer Risk: Though the relationship is complex, some studies suggest high DHT levels may influence prostate cancer progression. According to recent clinical reviews, men over the age of 50 are especially vulnerable, with over 50% developing some form of prostate enlargement by age 60. Treatment Options to Lower Elevated DHT Levels: Medical professionals emphasize early intervention and hormone regulation as key strategies. The most common treatments include: 1. 5-Alpha Reductase Inhibitors: Medications such as finasteride (Proscar) and dutasteride (Avodart) block the conversion of testosterone to DHT, reducing prostate size and alleviating symptoms. 2. Natural DHT Blockers: Compounds like saw palmetto extract, pumpkin seed oil, and green tea catechins are under investigation for their mild DHT-lowering effects. 3. Lifestyle Changes: A diet rich in anti-inflammatory foods, regular exercise, and weight management may help regulate hormone levels. 4. Hormonal Monitoring: Regular blood tests to track testosterone and DHT levels can aid in early detection and intervention. Dr. Michael Reynolds, a board-certified urologist, commented, “DHT is essential, but when imbalanced, it can become a catalyst for prostate issues. We now have evidence-based strategies to bring levels back to a healthier range.” About the Prostate Health Initiative The Prostate Health Initiative is a nationwide educational campaign aimed at raising awareness about male hormone balance and its effects on long-term urological health. Through collaboration with healthcare providers and research institutions, the initiative seeks to empower men to make informed choices about their prostate health. ________________________________________ Chris Rue Metairie Optimal Performance Enhancement +1 504-265-5491 info@mopeclinic.com Visit us on social media: LinkedIn Facebook Legal Disclaimer: EIN Presswire provides this news content "as is" without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the author above.